Literature DB >> 23072338

IFN-α subtypes: distinct biological activities in anti-viral therapy.

K Gibbert1, J F Schlaak, D Yang, U Dittmer.   

Abstract

During most viral infections, the immediate host response is characterized by an induction of type I IFN. These cytokines have various biological activities, including anti-viral, anti-proliferative and immunomodulatory effects. After induction, they bind to their IFN-α/β receptor, which leads to downstream signalling resulting in the expression of numerous different IFN-stimulated genes. These genes encode anti-viral proteins that directly inhibit viral replication as well as modulate immune function. Thus, the induction of type I IFN is a very powerful tool for the host to fight virus infections. Many viruses evade this response by various strategies like the direct suppression of IFN induction or inhibition of the IFN signalling pathway. Therefore, the therapeutic application of exogenous type I IFN or molecules that induce strong IFN responses should be of great potential for future immunotherapies against viral infections. Type I IFN is currently used as a treatment in chronic hepatitis B and C virus infection, but as yet is not widely utilized for other viral infections. One reason for this restricted clinical use is that type I IFN belongs to a multigene family that includes 13 different IFN-α subtypes and IFN-β, whose individual anti-viral and immunomodulatory properties have so far not been investigated in detail to improve IFN therapy against viral infections in humans. In this review, we summarize the recent achievements in defining the distinct biological functions of type I IFN subtypes in cell culture and in animal models of viral infection as well as their clinical usage in chronic hepatitis virus infections.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23072338      PMCID: PMC3594665          DOI: 10.1111/bph.12010

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  111 in total

1.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

2.  The in vivo expression patterns of individual type I interferon genes in murine cytomegalovirus infections.

Authors:  W S Yeow; C M Lai; M W Beilharz
Journal:  Antiviral Res       Date:  1997-03       Impact factor: 5.970

3.  Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.

Authors:  J G McHutchison; T Poynard
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

4.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

Authors:  Stefan Zeuzem; Mark S Sulkowski; Eric J Lawitz; Vinod K Rustgi; Maribel Rodriguez-Torres; Bruce R Bacon; Mircea Grigorescu; Alan D Tice; Yoav Lurie; Janusz Cianciara; Andrew J Muir; Patrick W Cronin; Erik Pulkstenis; G Mani Subramanian; John G McHutchison
Journal:  Gastroenterology       Date:  2010-06-27       Impact factor: 22.682

5.  Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Authors:  Agnes Le Bon; Vanessa Durand; Elisabeth Kamphuis; Clare Thompson; Silvia Bulfone-Paus; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

7.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.

Authors:  Patrick Marcellin; Ferruccio Bonino; George K K Lau; Patrizia Farci; Cihan Yurdaydin; Teerha Piratvisuth; Rui Jin; Selim Gurel; Zhi-Meng Lu; Jian Wu; Matei Popescu; Stephanos Hadziyannis
Journal:  Gastroenterology       Date:  2009-03-19       Impact factor: 22.682

8.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

9.  Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes.

Authors:  Wibke Bayer; Ruth Lietz; Teona Ontikatze; Lena Johrden; Matthias Tenbusch; Ghulam Nabi; Simone Schimmer; Peter Groitl; Hans Wolf; Cassandra M Berry; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  Retrovirology       Date:  2011-09-26       Impact factor: 4.602

10.  Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection.

Authors:  Kathrin Gibbert; Jara J Joedicke; Andreas Meryk; Mirko Trilling; Sandra Francois; Janine Duppach; Anke Kraft; Karl S Lang; Ulf Dittmer
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

View more
  67 in total

1.  Induction of IFN-α subtypes and their antiviral activity in mumps virus infection.

Authors:  Maja Markušić; Maja Šantak; Tanja Košutić-Gulija; Mladen Jergović; Renata Jug; Dubravko Forčić
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

Review 2.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 3.  Interferons: Success in anti-viral immunotherapy.

Authors:  Fan-ching Lin; Howard A Young
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

4.  In vivo evaluation of the efficacy of combined albedazole-IFN-α treatment for cystic echinococcosis in mice.

Authors:  Shengbin Zhang; Yongsheng Zhou; Lifu Su; Xiaodong Zhang; Hao Wang; Baoqin Liu
Journal:  Parasitol Res       Date:  2016-12-07       Impact factor: 2.289

5.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

6.  Viral infections associated with oral cancers and diseases in the context of HIV: a workshop report.

Authors:  D J Speicher; V Ramirez-Amador; D P Dittmer; J Webster-Cyriaque; M T Goodman; A-B Moscicki
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

7.  Protection from interferon-β-induced neuronal apoptosis through stimulation of muscarinic acetylcholine receptors coupled to ERK1/2 activation.

Authors:  Maria C Olianas; Simona Dedoni; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2016-08-26       Impact factor: 8.739

8.  A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Authors:  S Miersch; S Kuruganti; M R Walter; S S Sidhu
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

9.  Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication.

Authors:  Daniel Todt; Catherine François; Patrick Behrendt; Michael Engelmann; Leonard Knegendorf; Gabrielle Vieyres; Heiner Wedemeyer; Rune Hartmann; Thomas Pietschmann; Gilles Duverlie; Eike Steinmann
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 10.  Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.

Authors:  Xiaoting Wang; Kit Wong; Wenjun Ouyang; Sascha Rutz
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-02-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.